{
    "root": "65cfb382-8f01-4ee8-8235-8ce2f5d3beec",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Rivastigmine Tartrate",
    "value": "20250303",
    "ingredients": [
        {
            "name": "RIVASTIGMINE TARTRATE",
            "code": "9IY2357JPE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_64358"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "HYPROMELLOSE 2910 (5 MPA.S)",
            "code": "R75537T0T4",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5291"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16189"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32035"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16134"
        }
    ],
    "indications": {
        "text": "rivastigmine tartrate capsules acetylcholinesterase inhibitor indicated treatment : \u2022 mild-to-moderate dementia alzheimer \u2019 type ( Alzheimer 's disease ) ( 1.1 ) \u2022 mild-to-moderate dementia associated parkinson \u2019 disease ( pd ) ( 1.2 )",
        "doid_entities": [
            {
                "text": "dementia (DOID:1307)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1307"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "alzheimer \u2019 disease ( 2.1 ) : \u2022 initial dose : initiate treatment 1.5 mg twice day . \u2022 dose titration : minimum 2 weeks , tolerated , increase dose 3 mg twice day 4.5 mg twice day 6 mg twice day tolerated minimum 2 weeks dose parkinson \u2019 disease dementia ( pdd ) ( 2.2 ) : \u2022 initial dose : initiate treatment 1.5 mg twice day . \u2022 dose titration : minimum 4 weeks , tolerated , increase dose 3 mg twice day 4.5 mg twice day 6 mg twice day tolerated minimum 4 weeks dose . rivastigmine tartrate capsules taken meals divided doses morning evening ( 2.1 , 2.2 ) . rivastigmine tartrate oral solution rivastigmine tartrate capsules may interchanged equal doses ( 2.4 ) .",
        "doid_entities": [
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "dementia (DOID:1307)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1307"
            },
            {
                "text": "pdd (DOID:0060042)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0060042"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "rivastigmine tartrate capsules , usp equivalent 1.5 mg , 3 mg , 4.5 mg , 6 mg rivastigmine base available follows : rivastigmine tartrate capsules usp , 1.5 mg yellow cap yellow body colored size \u2018 2 \u2019 capsules imprinted black ink \u2018 h \u2019 cap \u2018 67 \u2019 body , containing white off-white granular powder . cartons 100 capsules ( 10 capsules blister pack x 10 ) , ndc 0904-7107-61 store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) [ usp controlled room temperature ] . store tight container .",
    "adverseReactions": "rivastigmine tartrate capsules contraindicated patients : \u2022known hypersensitivity rivastigmine , carbamate derivatives components formulation [ description ( 11 ) ] \u2022a previous history application site reaction rivastigmine transdermal patch suggestive allergic contact dermatitis , absence negative allergy testing [ ( 5.2 ) ] isolated cases generalized skin described postmarketing experience [ ( 6.2 ) ] .",
    "indications_original": "Rivastigmine tartrate capsules are an acetylcholinesterase inhibitor indicated for treatment of: \u2022 Mild-to-moderate dementia of the Alzheimer\u2019s type (AD) ( 1.1 ) \u2022 Mild-to-moderate dementia associated with Parkinson\u2019s disease (PD) ( 1.2 )",
    "contraindications_original": "Alzheimer\u2019s Disease ( 2.1 ) : \u2022 Initial Dose: Initiate treatment with 1.5 mg twice a day. \u2022 Dose Titration: After a minimum of 2 weeks, if tolerated, increase dose to 3 mg twice a day and further to 4.5 mg twice a day and 6 mg twice a day if tolerated with a minimum of 2 weeks at each dose Parkinson\u2019s Disease Dementia (PDD) ( 2.2 ) : \u2022 Initial Dose: Initiate treatment with 1.5 mg twice a day. \u2022 Dose Titration: After a minimum of 4 weeks, if tolerated, increase dose to 3 mg twice a day and further to 4.5 mg twice a day and 6 mg twice a day if tolerated with a minimum of 4 weeks at each dose. Rivastigmine tartrate capsules should be taken with meals in divided doses in the morning and evening ( 2.1 , 2.2 ). Rivastigmine tartrate oral solution and rivastigmine tartrate capsules may be interchanged at equal doses ( 2.4 ).",
    "warningsAndPrecautions_original": "Rivastigmine tartrate capsules, USP equivalent to 1.5 mg, 3 mg, 4.5 mg, or 6 mg of rivastigmine base are available as follows:\n                     \n                      Rivastigmine Tartrate  Capsules USP, 1.5 mg are yellow cap and yellow body colored size \u20182\u2019 capsules imprinted in black ink with \u2018H\u2019 on cap and \u201867\u2019 on body, containing white to off-white granular powder.\n                     Cartons of 100 capsules (10 capsules each blister pack x 10), NDC 0904-7107-61\n                     \n                      Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) [see USP Controlled Room Temperature]. Store in a tight container.",
    "adverseReactions_original": "Rivastigmine tartrate capsules are contraindicated in patients with:\n                  \n                     \n                        \u2022known hypersensitivity to rivastigmine, other carbamate derivatives or other components of the formulation [see Description (11)]\n                     \n                     \n                        \u2022a previous history of application site reaction with rivastigmine transdermal patch suggestive of allergic contact dermatitis, in the absence of negative allergy testing [see Warnings and Precautions (5.2)]\n                     \n                  \n                  Isolated cases of generalized skin reactions have been described in postmarketing experience [see Adverse Reactions (6.2)].",
    "drug": [
        {
            "name": "Rivastigmine Tartrate",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_64358"
        }
    ]
}